Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics

Journal of Clinical Investigation

Volumn 115, Issue 1, 2005, Pages 110-117

  Kager, Leo ^a,b   Cheok, Meyling ^a   Yang, Wenjian ^a   Zaza, Gianluigi ^a   Cheng, Qing ^a   Panetta, John C ^a   Pui, Ching Hon ^a,c   Downing, James R ^a   Relling, Mary V ^a,c   Evans, William E ^a,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b ST ANNA CHILDREN S HOSPITAL   (Austria)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; FOLIC ACID; FOLINIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; METHOTREXATE; METHOTREXATE POLYGLUTAMATE; REDUCED FOLATE CARRIER; DNA; DRUG DERIVATIVE; MESSENGER RNA; POLYGLUTAMIC ACID; THYMIDYLATE SYNTHASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AML1 GENE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LEUKEMIA; CANCER CLASSIFICATION; CELL LINEAGE; CHILD; CONTROLLED STUDY; DNA MICROARRAY; DRUG ACCUMULATION; E2A GENE; FOLATE METABOLISM; GENE; GENE EXPRESSION; GENE FUSION; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKEMIA CELL; MAJOR CLINICAL STUDY; PBX1 GENE; PHARMACODYNAMICS; PRIORITY JOURNAL; T CELL LEUKEMIA; TEL GENE; TREATMENT FAILURE; ACUTE LYMPHOCYTIC LEUKEMIA; BIOSYNTHESIS; CLASSIFICATION; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; LEUKOCYTE COUNT; LYMPHOCYTE; METABOLISM; PATHOLOGY;

CLUSTER ANALYSIS; DNA; FOLIC ACID; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKOCYTE COUNT; LYMPHOCYTES; METHOTREXATE; POLYGLUTAMIC ACID; RNA, MESSENGER; THYMIDYLATE SYNTHASE;

EID: 85047692068     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI22477     Document Type: Article

References (54)

1. Pui, C.H., Relling, M.V., and Downing, J.R. 2004. Acute lymphoblastic leukemia. N. Engl. J. Med. 350:1535-1548.
2. Zhao, R., and Goldman, I.D. 2003. Resistance to antifolates. Oncogene. 22:7431-7457.
3. Masson, E., et al. 1996. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J. Clin. Invest. 97:73-80.
4. Curt, G.A., et al. 1985. Determinants of the sensitivity of human small-cell lung cancer cell lines to methotrexate. J. Clin. Invest. 76:1323-1329.
5. Jolivet, J., Cowan, K.H., Curt, G.A., Clendeninn, N.J., and Chabner, B.A. 1983. The pharmacology and clinical use of methotrexate. N. Engl. J. Med. 309:1094-1104.
6. Allegra, C.J., et al. 1985. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J. Biol. Chem. 260:9720-9726.
7. Allegra, C.J., Drake, J.C., Jolivet, J., and Chabner, B.A. 1985. Inhibition of phosphoribosylamino-imidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc. Natl. Acad. Sci. U. S. A. 82:4881-4885.
8. Relling, M.V., et al. 1994. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J. Clin. Oncol. 12:1667-1672.
9. Gorlick, R., et al. 1996. Intrinsic and acquired resistance to methotrexate in acute leukemia. N. Engl. J. Med. 335:1041-1048.
10. Hooijberg, J.H., et al. 1999. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 59:2532-2535.
11. Zeng, H., Chen, Z.S., Belinsky, M.G., Rea, P.A., and Kruh, G.D. 2001. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 61:7225-7232.
12. Chen, Z.S., et al. 2002. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 62:3144-3150.
13. Volk, E.L., and Schneider, E. 2003. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 63:5538-5543.
14. Gifford, A.J., et al. 1998. P-glycoprotein-mediated methotrexate resistance in CCRF-CEM sublines deficient in methotrexate accumulation due to a point mutation in the reduced folate carrier gene. Int. J. Cancer. 78:176-181.
15. McGuire, J.J., and Bertino, J.R. 1981. Enzymatic synthesis and function of folylpolyglutamates. Mol. Cell. Biochem. 38(Spec. No.):19-48.
16. Galivan, J., et al. 2000. Glutamyl hydrolase. Pharmacological role and enzymatic characterization. Pharmacol. Ther. 85:207-215.
17. Whitehead, V.M., et al. 1992. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood. 80:1316-1323.
18. Whitehead, V.M., et al. 1998. Accumulation of methotrexate polyglutamates, ploidy and trisomies of both chromosomes 4 and 10 in lymphoblasts from children with B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Lenk. Lymphoma. 31:507-519.
19. Whitehead, V.M., et al. 2001. The association of the TEL-AML1 chromosomal translocation with the accumulation of methotrexate polyglutamates in lymphoblasts and with ploidy in childhood B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Leukemia. 15:1081-1088.
20. Synold, T.W., et al. 1994. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J. Clin. Invest. 94:1996-2001.
21. Barredo, J.C., et al. 1994. Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood. 84:564-569.
22. Galpin, A.J., et al. 1997. Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Mol. Pharmacol. 52:155-163.
23. Rots, M.G., et al. 1999. Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. Blood. 93:1677-1683.
24. Zhang, L., et al. 1998. Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: relationship to immunophenotype and ploidy. Clin. Cancer Res. 4:2169-2177.
25. Belkov, V.M., et al. 1999. Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood. 93:1643-1650.
26. Cheng, Q., et al. 2004. A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. Pharmacogenetics. 14:557-567.
27. Suh, J.R., Oppenheim, E.W., Girgis, S., and Stover, P.J. 2000. Purification and properties of a folate-catabolizing enzyme. J. Biol. Chem. 275:35646-35655.
28. Foa, R., et al. 2003. E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. Br. J. Haematol. 120:484-487.
29. Crist, W.M., et al. 1990. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood. 76:117-122.
30. Raimondi, S.C., et al. 1990. Cytogenetics of pre-B-cell acute lymphoblastic leukemia with emphasis on prognostic implications of the t(1;19). J. Clin. Oncol. 8:1380-1388.
31. Pui, C.H., et al. 2003. Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA 290:2001-2007.
32. Trippett, T., et al. 1992. Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia. Blood. 80:1158-1162.
33. Gorlick, R., et al. 1997. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood. 89:1013-1018.
34. Sierra, E.E., and Goldman, I.D. 1999. Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates. Semin. Oncol. 26:11-23.
35. Schrappe, M., et al. 2000. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 95:3310-3322.
36. Hooijberg, J.H., et al. 2003. The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis. Biochem. Pharmacol. 65:765-771.
37. Hooijberg, J.H., et al. 2004. Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem. Pharmacol. 67:1541-1548.
38. Assaraf, Y.G., et al. 2003. Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells. J. Biol. Chem. 278:6680-6686.
39. Volk, E.L, et al. 2002. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res. 62:5035-5040.
40. Plasschaert, S.L., et al. 2003. The role of breast cancer resistance protein in acute lymphoblastic leukemia. Clin. Cancer Res. 9:5171-5177.
41. DeGregori, J. 2002. The genetics of the E2F family of transcription factors: shared functions and unique roles. Biochim. Biophys. Acta. 1602:131-150.
42. Li, W.W., Fan, J., Hochhauser, D., and Bertino, J.R. 1997. Overexpression of p21waf1 leads to increased inhibition of E2F-1 phosphorylation and sensitivity to anticancer drugs in retinoblastoma-negative human sarcoma cells. Cancer Res. 57:2193-2199.
43. Rots, M.G., et al. 2000. mRNA expression levels of methotrexate resistance-related proteins in child-hood leukemia as determined by a standardized competitive template-based RT-PCR method. Leukemia. 14:2166-2175.
44. Zaza, G., et al. 2004. Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis. Blood. 104:1435-1441.
45. Uckun, F.M., et al. 1998. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood. 91:735-746.
46. Dervieux, T., et al. 2002. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood. 100:1240-1247.
47. Ross, M.E., et al. 2003. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood. 102:2951-2959.
48. D'Argenio, D.Z. 1990. Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. Math. Biosci. 99:105-118.
49. Lipshutz, R.J., Fodor, S.P., Gingeras, T.R., and Lockhart, D.J. 1999. High density synthetic oligonucleotide arrays. Nat. Genet. 21:20-24.
50. National Center for Biotechnology Information. http://www.ncbi.nlm.nih. gov.
51. KEGG: Kyoto Encyclopedia of Genes and Genomes. http://www.genome.ad.jp/ kegg.
52. Westfall, P.H., Zaykin, D.V., and Young, S.S. 2002. Multiple tests for genetic effects in association studies. Methods Mol. Biol. 184:143-168.
53. Match-Public, http://www.gene-regulation.com/pub/programs.html#match.
54. The R project for Statistical Computing, http://www.r-project.org.